2026-2032 年 COVID-19 疫苗市場（按技術、應用和地區）

COVID-19疫苗市場評估-2026-2032

社會對疫苗益處的認知不斷提高，導致對新冠疫苗接種的需求增加。隨著各國政府和組織加大對疫苗接種的資金投入和支持，預計2024年市場規模將超過76.4億美元，到2032年將達到約126.4億美元。

此外，疫苗研發和配送方法的創新提高了生產效率和分銷管道，也刺激了新冠疫苗的推廣。製藥公司、政府和非政府組織之間的夥伴關係正在加速疫苗研發和分銷工作，推動市場在2026年至2032年期間的複合年成長率達到7.16%。

COVID-19 疫苗市場：定義/概述

COVID-19 疫苗是生物製藥，旨在幫助您獲得對導致 COVID-19 的 SARS-CoV-2 病毒的免疫力。這些疫苗的工作原理是將病毒的無害成分（例如刺突蛋白或 mRNA）引入體內，以便您的免疫系統在將來接觸病毒時識別並做出反應，從而幫助預防重症和感染。

新冠疫苗的應用對控制疫情至關重要。疫苗宣傳活動旨在實現人群廣泛免疫，並顯著降低了與病毒相關的住院率和死亡率。除了個人保護外，廣泛接種疫苗還有助於形成群體免疫，有助於減少病毒傳播，促進社會正常運作的恢復。

人們對兒童疫苗接種的興趣增加將如何促進 COVID-19 疫苗的採用？

全球疫苗接種率的上升推動了新冠疫苗市場的發展，世界各國政府都在實施全面的疫苗接種計畫。根據世界衛生組織統計，截至2023年12月，全球已接種新冠疫苗135億劑，市場滲透率龐大。新變種的出現持續推動對更新劑型的需求，同時，衛生組織也強調了對弱勢族群進行加強接種的重要性。

疫苗平台的技術進步，尤其是mRNA技術的進步，改變了市場格局。美國疾病管制與預防中心報告稱，在2020-2021年的早期試驗中，mRNA疫苗在預防重症新冠肺炎病例方面顯示超過90%的有效率。 2023年9月，輝瑞和Moderna推出了針對較新的Omicron變體的升級版單價XBB.1.5疫苗，擴大了其市場佔有率。

兒童疫苗和針對免疫力缺乏患者的特殊製劑日益受到關注，這正在創造新的市場機會。根據歐洲藥品管理局 (EMA) 的數據，到 2023 年中期，歐盟/歐洲經濟區約 82% 的 12-17 歲兒童將接種至少一劑新冠疫苗。近期，諾瓦瓦克斯 (Novavax) 宣布其新冠-流感聯合疫苗將於 2024 年 3 月成功進行臨床試驗，這可能會徹底改變季節性疫苗接種方式，並擴大市場潛力。

哪些供應鏈中斷阻礙了 COVID-19 疫苗市場的成長？

新冠疫苗市場面臨諸多限制因素，可能影響其成長和可及性。其中一個主要限制因素是疫苗猶豫，即個人由於錯誤訊息、對副作用的擔憂以及對製藥公司的不信任而不願或拒絕接種疫苗。這種猶豫導致疫苗接種率下降，損害了公共衛生工作，並延長了疫情。

供應鏈中斷也為新冠疫苗市場帶來了重大挑戰。疫苗的快速研發和推廣給生產和分銷網路帶來了巨大壓力。原料短缺、運輸問題和物流挑戰等因素可能會導致疫苗供應延遲，尤其是在中低收入國家。

監管障礙也給疫苗開發商帶來了挑戰，因為他們必須應對每個國家複雜的核准流程。監管標準的差異可能會減緩新疫苗的推出，並限制市場擴張。此外，還需要持續進行監測和上市後研究，以監測疫苗的安全性和有效性，這進一步增加了核准流程的複雜性。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

4. COVID-19 疫苗市場（依技術）

• mRNA疫苗
• 病毒載體疫苗
• DNA疫苗
• 蛋白質次單元疫苗
• 去活化疫苗

5. COVID-19 疫苗市場（按應用）

• 初次接種
• 加強疫苗接種

第7章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第8章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第9章 競爭態勢

• 主要企業
• 市場佔有率分析

第10章 公司簡介

• Pfizer
• Moderna
• AstraZeneca
• Johnson & Johnson
• Sinopharm
• Sinovac Biotech
• Bharat Biotech

第11章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第12章 附錄

• 簡稱列表
• 來源和參考文獻

Covid-19 Vaccine Market Valuation - 2026-2032

Growing public understanding of vaccine benefits, leading to higher demand for COVID-19 vaccinations. Increased funding and support from governments and organizations to promote vaccination efforts worldwide is driving the market size surpass USD 7.64 Billion valued in 2024 to reach a valuation of around USD 12.64 Billion by 2032.

In addition to this, innovations in vaccine development and delivery methods enhancing production efficiency and distribution is spurring up the adoption of Covid-19 vaccine. Partnerships between pharmaceutical companies, governments, and NGOs accelerating research and distribution efforts is enabling the market to grow at a CAGR of 7.16% from 2026 to 2032.

Covid-19 Vaccine Market: Definition/ Overview

A COVID-19 vaccine is a biological preparation designed to provide immunity against the SARS-CoV-2 virus, which causes COVID-19. These vaccines work by introducing a harmless component of the virus, such as a spike protein or mRNA, into the body. This triggers the immune system to recognize and respond to the virus if exposed in the future, helping to prevent severe illness and transmission.

The application of COVID-19 vaccines has been crucial in controlling the pandemic. Vaccination campaigns have aimed to achieve widespread immunity in populations, significantly reducing hospitalization rates and deaths associated with the virus. In addition to individual protection, widespread vaccination contributes to herd immunity, helping to limit the virus's spread and facilitating the return to normal societal functions.

How will Growing Focus on Pediatric Vaccinations Increase Adoption of Covid-19 Vaccine?

Rising global vaccination rates have propelled the Covid-19 vaccine market forward, with governments worldwide implementing comprehensive immunization programs. According to the WHO, as of December 2023, over 13.5 billion Covid-19 vaccine doses had been administered globally, demonstrating massive market penetration. The emergence of new variants continues to drive demand for updated formulations, while health organizations emphasize the importance of booster doses for vulnerable populations.

Technological advancements in vaccine platforms have revolutionized the market landscape, particularly through mRNA technology. The US CDC reported that mRNA vaccines showed over 90% efficacy in preventing severe Covid-19 cases during initial trials in 2020-2021. In September 2023, Pfizer and Moderna launched their updated monovalent XBB.1.5 vaccines, targeting newer Omicron subvariants and expanding their market presence.

Growing focus on pediatric vaccinations and specialized formulations for immunocompromised individuals has created new market opportunities. The European Medicines Agency (EMA) data showed that approximately 82% of children aged 12-17 in the EU/EEA received at least one Covid-19 vaccine dose by mid-2023. Recently, Novavax announced successful trials of its combination Covid-19-influenza vaccine in March 2024, potentially revolutionizing the seasonal vaccination approach and expanding market possibilities.

How Supply Chain Disruptions Hampering Covid-19 Vaccine Market Growth?

The COVID-19 vaccine market faces several restraints that can impact its growth and accessibility. One major constraint is vaccine hesitancy, where individuals may be reluctant or refuse to receive the vaccine due to misinformation, fear of side effects, or distrust in pharmaceutical companies. This hesitancy can lead to lower vaccination rates, undermining public health efforts and prolonging the pandemic.

Supply chain disruptions have also posed significant challenges to the COVID-19 vaccine market. The rapid development and deployment of vaccines put immense pressure on manufacturing and distribution networks. Factors such as shortages of raw materials, transportation issues, and logistical challenges can lead to delays in vaccine availability, particularly in low- and middle-income countries.

Regulatory hurdles represent another restraint, as vaccine developers must navigate complex approval processes in various countries. Differences in regulatory standards can slow down the introduction of new vaccines and limit market expansion. Additionally, ongoing surveillance and post-marketing studies are necessary to monitor vaccine safety and efficacy, which can further complicate the approval process.

Category-Wise Acumens

Will Rise in Adoption of mRNA Technology Drive Covid-19 Vaccine Market Growth?

mRNA technology is expected to dominate Covid-19 vaccine market. The revolutionary mRNA technology is emerging as a game-changer in the Covid-19 vaccine landscape, offering unprecedented speed in vaccine development and manufacturing. According to the US FDA, mRNA vaccines demonstrated remarkable efficacy rates of 94-95% in preventing symptomatic Covid-19 infections during initial clinical trials in 2020. Moderna and Pfizer-BioNTech's success with mRNA platforms has sparked increased investment in this technology, with both companies announcing expanded research facilities and enhanced production capabilities throughout 2023 to meet global demand.

The adaptability of mRNA technology has proven crucial in responding to emerging variants, enabling rapid modification of vaccine formulations. The European Medicines Agency reported that over 600 million mRNA vaccine doses were administered in the EU/EEA by December 2023, establishing them as the predominant vaccine type. In February 2024, Moderna announced positive results from its next-generation mRNA platform trials, promising enhanced stability at regular refrigeration temperatures and potentially eliminating the ultra-cold storage requirement that initially challenged distribution.

Will Rise in Adoption of Booster Dose Drive Covid-19 Vaccine Market Growth?

Booster dose is anticipated to hold major share in the Covid-19 vaccine market. The increasing emphasis on booster doses has become a significant driver in the Covid-19 vaccine market, as health authorities worldwide recommend additional shots to maintain immunity levels. The US CDC reported that by January 2024, over 56.5% of eligible adults had received at least one booster dose, highlighting substantial market potential. Major manufacturers like Pfizer-BioNTech and Moderna have adapted their production strategies to meet this sustained demand, with both companies releasing variant-specific boosters targeting the latest strains.

Growing evidence supporting the effectiveness of booster doses in preventing severe illness has strengthened their market position. According to the UK Health Security Agency, booster shots provided 88% additional protection against hospitalization from the Omicron variant in studies conducted through 2023. In March 2024, Moderna announced positive trial results for its combination respiratory booster vaccine, which targets both Covid-19 variants and influenza strains, potentially revolutionizing the seasonal vaccination approach.

Country/Region-wise Acumens

Will Advanced Cold Chain Logistics in North America Drive Covid-19 Vaccine Market Growth?

North America maintains its leadership position in the global Covid-19 vaccine market through robust healthcare infrastructure and substantial government investments in vaccination programs. According to the US CDC, more than 674 million Covid-19 vaccine doses were administered in the United States by December 2023, demonstrating the region's massive vaccine uptake. The presence of major pharmaceutical companies and research institutions has further strengthened North America's market dominance, with recent expansions of manufacturing facilities by Pfizer in Michigan and Moderna in Massachusetts announced in early 2024.

Advanced cold chain logistics and efficient distribution networks have enabled seamless vaccine delivery across the continent, supporting market growth. Health Canada reported that approximately 83% of eligible Canadians completed their primary vaccination series by the end of 2023. Moderna's announcement in March 2024 regarding the establishment of a new research and development hub in Toronto, focusing on next-generation mRNA technologies, reinforces North America's position as a key innovation center for vaccine development.

Will Robust Healthcare Infrastructure Enhance Adoption of Covid-19 Vaccine in Asia Pacific?

North America maintains its leadership position in the global Covid-19 vaccine market through robust healthcare infrastructure and substantial government investments in vaccination programs. According to the US CDC, more than 674 million Covid-19 vaccine doses were administered in the United States by December 2023, demonstrating the region's massive vaccine uptake. The presence of major pharmaceutical companies and research institutions has further strengthened North America's market dominance, with recent expansions of manufacturing facilities by Pfizer in Michigan and Moderna in Massachusetts announced in early 2024.

Advanced cold chain logistics and efficient distribution networks have enabled seamless vaccine delivery across the continent, supporting market growth. Health Canada reported that approximately 83% of eligible Canadians completed their primary vaccination series by the end of 2023. Moderna's announcement in March 2024 regarding the establishment of a new research and development hub in Toronto, focusing on next-generation mRNA technologies, reinforces North America's position as a key innovation center for vaccine development.

Competitive Landscape

The Covid-19 vaccine market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the Covid-19 vaccine market include:

• Pfizer-BioNTech
• Moderna
• AstraZeneca
• Johnson & Johnson (Janssen)
• Novavax
• Sinovac Biotech
• Sinopharm
• Sputnik V (Gamaleya Research Institute)
• Bharat Biotech
• COVAXIN (Bharat Biotech)
• CanSino Biologics
• Zydus Cadila
• Valneva
• Merck & Co.
• Sanofi
• GSK (GlaxoSmithKline)
• CureVac
• Vaxart
• ModernaTX
• Inovio Pharmaceuticals

Latest Developments

• In October 2023, several pharmaceutical companies announced the results of clinical trials for new Covid-19 vaccines aimed at emerging variants, demonstrating increased efficacy and safety profiles.
• In September 2023, the WHO approved a new vaccine platform designed for rapid development and deployment in response to future Covid-19 variants, enhancing global readiness.

Covid-19 Vaccine Market, By Category

• Technology:
• mRNA Technology
• Viral Vector Technology
• Protein Subunit Technology
• DNA Technology
• Application:
• Primary Vaccination
• Booster Doses
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Covid-19 Vaccine Market, By Technology

• mRNA vaccines
• Viral Vector Vaccines
• DNA vaccines
• Protein Subunit Vaccines
• Inactivated Vaccines

5. Covid-19 Vaccine Market, By Application

• Primary Vaccination
• Booster doses: Given

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Pfizer
• Moderna
• AstraZeneca
• Johnson & Johnson
• Sinopharm
• Sinovac Biotech
• Bharat Biotech

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References